enfuvirtide [Fuzeon]
Sponsors
Hoffmann-La Roche
Conditions
HIV Infections
Phase 2
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
CompletedNCT00089492
Start: 2004-07-31End: 2006-06-30Updated: 2016-11-02
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
CompletedNCT00615134
Start: 2008-01-31End: 2011-06-30Updated: 2015-01-27
Phase 4
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection
CompletedNCT00232908
Start: 2004-06-30End: 2005-10-31Updated: 2016-11-02
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
CompletedNCT00233883
Start: 2005-08-31End: 2006-07-31Updated: 2015-11-03
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
CompletedNCT00326963
Start: 2006-03-31End: 2007-05-31Updated: 2016-08-16
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
CompletedNCT00337701
Start: 2006-06-30End: 2007-01-31Updated: 2015-11-03
ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.
WithdrawnNCT00461266
Start: 2007-04-30End: 2008-01-31Updated: 2016-08-24
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
TerminatedNCT00488059
Start: 2007-06-30End: 2008-10-31Updated: 2011-07-22